MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
May 17 2021 - 09:00AM
Business Wire
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage
pharmaceutical company committed to extending healthy lifespan by
focusing on developing two therapeutic platforms, announced today
that it has appointed David Rini to the Company’s Scientific
Advisory Board.
“I am delighted to join the MyMD Scientific Advisory Board and
look forward to working on the development and communication about
our two platforms,” stated David Rini.
David Rini is a Professor at the Johns Hopkins University School
of Medicine in the Department of Art of Applied to Medicine,
Cellular and Molecular Medicine, and Director of the Medical and
Biological Illustration Graduate Program. Professor Rini earned his
M.F.A. degree in medical and scientific illustration from the
University of Michigan in 1989. Prior to coming to Johns Hopkins in
1993, he established and directed the Department of Neurosurgical
Illustration at the Mayfield Neurological Institute in Cincinnati,
Ohio.
Chris Chapman, M.D., President and Chief Medical Officer of MyMD
added, “We welcome David to our Scientific Advisory Board and look
forward to sharing the MyMD story with our new presentation due to
be aired today, May 17th at 4:15pm ET.”
- Event Link: www.webcaster4.com/Webcast/Page/2584/41075
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms. MYMD-1 is a drug platform based on a
clinical stage small molecule that regulates the immunometabolic
system to control TNF-α and other pro-inflammatory cytokines.
MYMD-1 is being developed to treat autoimmune diseases, including
those currently treated with non-selective TNF-α blocking drugs,
and aging and longevity. Supera-CBD is a drug platform based on a
novel (patent pending) synthetic derivative of cannabidiol (CBD)
that targets numerous key receptors including CB2 and opioid
receptors and inhibits monoamine oxidase. Supera-CBD is being
developed to address the rapidly growing CBD market, that includes
FDA approved drugs and CBD products not currently regulated as a
drug. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates, the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates, the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the registration statement on Form S-4 filed
by MyMD on January 15, 2021, as amended. Forward-looking statements
speak only as of the date they are made and MyMD disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210517005552/en/
Investor Contact: Brett Maas 646-536-7331
brett@haydenir.com www.haydenir.com
Media Contact: Will Johnson 201-465-8019
MYMD@antennagroup.com www.antennagroup.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2023 to Mar 2024